Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries

R. BIELEN ; S. R. STUMO ; R. HALFORD ; K. WERLING ; T. REIC ; H. STÖVER ; G. ROBAEYS ; J. V. LAZARUS | 2018
Dans Harm Reduction Journal (Vol.15, n°25, 2018) Article : Périodique

Background: Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although harm reduction service[...]

Plus d'info

Ajouter à la sélection

Lien externe

Nouveauté

Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint]

J. V. LAZARUS ; K. SAFREED-HARMON ; S. R. STUMO ; M. JAUFFRET-ROUSTIDE ; M. MATICIC ; T. REIC ; E. SCHATZ ; J. TALLADA ; M. HARRIS ; HEP-CORE STUDY GROUP | 2017
Dans International Journal of Drug Policy (Vol.47, September 2017) Article : Périodique

In 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatit[...]

Plus d'info

Ajouter à la sélection